Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous sonelokimab versus placebo in adults with moderate to severe hidradenitis suppurativa has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Sonelokimab (sonelokimab)

Snippet

Sponsor: MoonLake Immunotherapeutics AG | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: COMPLETED